Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung deal costs Biogen US$700mn

Executive Summary

Biogen has exercised its option to increase its ownership stake in Samsung Bioepis – its joint venture with Samsung BioLogics – from 5.4% to around 49.9%, at a cost of “approximately US$700 million”, subject to closing conditions. The exact share purchase price for the transaction – which is expected to close in the second half of 2018 – “will depend on the timing of the closing and foreign currency exchange rates at that time”, Biogen observed.

You may also be interested in...



Samsung Bioepis’ Etanercept Nod Prompts US Lawsuit

The FDA has approved Samsung Bioepis’ Eticovo as the second biosimilar competitor to Amgen’s blockbuster rheumatoid arthritis biologic Enbrel. Amgen immediately sued for patent infringement.

Benepali Surge And Imraldi Gains Drive Biogen Biosimilars Past US$500m

With sales climbing by more than two-fifths last year, Biogen expects its biosimilar sales to continue to grow by double digits in 2019, driven by the launch of the Imraldi adalimumab biosimilar in mid-October last year.

Japan Tirabrutinib Approval Breaks New BTK Ground In Lymphoma

Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.

Topics

UsernamePublicRestriction

Register

GB000911

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel